Hello, Secretary Dong, I have been following your company for a while. I would like to ask if your medical device division has mass-produced high-end CT medical equipment products? Have 64-row and 128-row CTs been mass-produced? Has Neusoft Medical's revenue been included in Neusoft Group's financial report this year? If Neusoft Medical is successfully listed, will it mean that the market value of Neusoft Group's assets will increase a lot? Thank you!!!

Neusoft Group: Hello, the R&D and manufacturing of high-end large medical equipment such as CT you mentioned is the main business of Neusoft Medical. As a joint-stock company in which the company holds approximately 30% of the shares, Neusoft Medical does not consolidate its revenue and uses the equity method to account for its profits. As a leading provider of medical imaging solutions and services, Neusoft Medical launched CT products as early as 1997 and began mass production and listing in 1998. It has begun exporting to the United States since 2003. Over the years, Neusoft Medical has relied on independent research and development to rewrite the history of the development of medical imaging equipment in China time and time again. Milestone innovations such as China's first CT, the first superconducting magnetic resonance imaging, and the first DR were all born in Neusoft Medical. In recent years, Neusoft Medical has continued to launch many new products such as China's first 256-layer 80mm wide-body energy spectrum CT, China's first 512-layer panoramic multimodal CT, trackless suspension dual-center seven-axis DSA, and 1.5T superconducting magnetic resonance imaging, leading domestic medical equipment to continue to move towards excellence and high-end. Neusoft Medical's products have been sold to more than 110 countries and regions around the world, with a historical installed base of more than 42,000 units. Currently, Neusoft Medical's listing is being carried out in accordance with the plan with the goal of realizing shareholder value. Thank you for your attention.